GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (OTCPK:NXSCF) » Definitions » Capex-to-Operating-Income

NXSCF (Next Science) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Next Science's Capital Expenditure for the six months ended in Dec. 2024 was $-0.26 Mil. Its Operating Income for the six months ended in Dec. 2024 was $-5.19 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Next Science Capex-to-Operating-Income Historical Data

The historical data trend for Next Science's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Capex-to-Operating-Income Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Next Science Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Next Science's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Next Science's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Next Science's Capex-to-Operating-Income falls into.


;
;

Next Science Capex-to-Operating-Income Calculation

Next Science's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.589) / -11.6
=N/A

Next Science's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.26) / -5.193
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Next Science  (OTCPK:NXSCF) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Next Science Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Next Science's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Next Science Business Description

Traded in Other Exchanges
Address
264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.

Next Science Headlines